PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-FTSE marks third straight day in the red

Wed, 22nd Jan 2020 09:31

* FTSE 100 down 0.5%, FTSE 250 up 0.1%

* Multinationals biggest drag on main index

* Berkeley leads housebuilders higher

* TUI, Burberry also weigh down bluechips

* Ted Baker slides among smallcaps
(Adds company news items, updates share moves)

By Shashwat Awasthi and Muvija M

Jan 22 (Reuters) - London's FTSE 100 recorded its longest
losing streak since early December as a strengthening in
sterling triggered by strong manufacturing sentiment data
weighed on dollar earners, while travel group TUI slid on more
Boeing woes.

The main index reversed earlier gains to decline
0.5% on its third consecutive day in the red.

Homebuilder Berkeley limited losses on the index,
jumping 5.4% to a record high after plans to return 450 million
pounds more to shareholders. An index of housebuilders
scaled over a two-year high on the news.

The FTSE 250 added 0.1%, buoyed by a stronger local
currency.

The pound scaling a five-week high against the euro came as
bets of a cut to the UK interest rate declined after the
Confederation of British Industry reported a pick-up in
manufacturers' sentiment.

That dragged on bluechip exporters including GlaxoSmithKline
, HSBC and British American Tobacco.

A standout faller was TUI, whose London-listed
shares slipped nearly 6% to their lowest since September after
Boeing warned of further delay in returning its grounded
737 MAX airliner to service.

The FTSE 100 missed out as world shares held firm after
Chinese authorities ramped up efforts to control the outbreak of
the coronavirus, which is being likened to the 2002-2003 spread
of Severe Acute Respiratory Syndrome (SARS) and has already led
to nine deaths.

Sage Group outperformed the bourse with a 4% rise as
the software provider reported higher quarterly revenue and
affirmed its annual forecast.

But Burberry slid 5% despite a solid performance
through the Christmas quarter.

"The reminder of how closely the company's fortunes are tied
to China may have provoked some nervousness given the deadly
virus which is currently afflicting the country," AJ Bell
investment director Russ Mould said.

He also suggested that there could be a hint of
profit-taking, given the recent rally in shares.

Further driving the index lower was a dip in Shell
and BP as oil prices weakened, and miner Antofagasta
which fell 4.6% after its copper production was hit by
civil unrest in Chile.

Small-cap fashion retailer Ted Baker sank as much as
10% after it more than doubled its preliminary estimate of an
overstatement in inventory.

A combination of multiple profit warnings, subdued consumer
sentiment and a slew of management changes after allegations of
misconduct against founder Ray Kelvin had knocked more than 70%
off the stock's value last year.
(Reporting by Shashwat Awasthi and Muvija M in Bengaluru;
Editing by Angus MacSwan)

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.